<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461901</url>
  </required_header>
  <id_info>
    <org_study_id>14/NW/1398</org_study_id>
    <nct_id>NCT02461901</nct_id>
  </id_info>
  <brief_title>Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?</brief_title>
  <official_title>Does Using Fidaxomicin to Treat Clostridium Difficile Infection (CDI) Reduce the Recovery of C. Difficile From Patients' Faeces, Skin and Their Immediate Environment, Compared to Treatment With Vancomycin or Metronidazole?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Mark Wilcox</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St George's Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether patients with Clostridium difficile infection (CDI) who are&#xD;
      treated with fidaxomicin have less contamination of their skin and surrounding environment&#xD;
      with spores of C. difficile than patients treated with other drugs (metronidazole or&#xD;
      vancomycin)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fidaxomicin is a newly licensed drug for the treatment of CDI. Patients treated with&#xD;
      fidaxomicin have a significantly lower C. difficile spore count in their faeces than patients&#xD;
      who receive alternative drugs (metronidazole or vancomycin). In vitro evidence has shown that&#xD;
      the drug persists in the gut for several weeks after treatment has finished and also prevents&#xD;
      the outgrowth of spores. These findings suggest that fidaxomicin therapy could be associated&#xD;
      with less contamination of CDI patient's skin and their surrounding environment than&#xD;
      metronidazole or vancomycin therapy.&#xD;
&#xD;
      This prospective, case control study aims to investigate this hypothesis by measuring C.&#xD;
      difficile spore counts in patient's stool samples, on their skin and in the surrounding&#xD;
      environment. Results for patients receiving fidaxomicin will be compared with those on either&#xD;
      metronidazole or vancomycin.&#xD;
&#xD;
      If fidaxomicin therapy does reduce contamination levels, it might be a useful adjunct to&#xD;
      existing measures used to control CDI in healthcare settings, particularly in outbreak&#xD;
      situations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of environmental contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.</measure>
    <time_frame>Up to 28 days after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The presence of skin contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.</measure>
    <time_frame>Up to 28 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C.difficile spore counts in the faeces of CDI patients before, during and after treatment with fidaxomicin, vancomycin or metronidazole.</measure>
    <time_frame>Up to 28 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total C. difficile spore counts from skin swab samples during and following treatment with fidaxomicin, vancomycin or metronidazole.</measure>
    <time_frame>Up to 28 days after treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">203</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Fidaxomicin treatment</arm_group_label>
    <description>Patients being treat with fidaxomicin (on the decision of their treating physician)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole or vancomycin treatment</arm_group_label>
    <description>Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Environmental sampling</intervention_name>
    <description>Sampling of five sites in the patient's immediate environment for C. difficile spores</description>
    <arm_group_label>Fidaxomicin treatment</arm_group_label>
    <arm_group_label>Metronidazole or vancomycin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin swab sampling</intervention_name>
    <description>Collection of swabs from three sites on the skin for C. difficile spores</description>
    <arm_group_label>Fidaxomicin treatment</arm_group_label>
    <arm_group_label>Metronidazole or vancomycin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal sampling</intervention_name>
    <description>Collection of fecal samples for C. difficile spores</description>
    <arm_group_label>Fidaxomicin treatment</arm_group_label>
    <arm_group_label>Metronidazole or vancomycin treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Isolates of Clostridium difficile&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Clostridium difficile infection.&#xD;
&#xD;
        CDI is defined as the presence of both:&#xD;
&#xD;
          -  a positive C. difficile toxin assay result on a fecal sample, and&#xD;
&#xD;
          -  diarrhea (Bristol stool type 5-7) &gt;/= 3 times in any 24 hour period in the last 7 days&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CDI (see above)&#xD;
&#xD;
          -  Prescribed fidaxomicin, vancomycin or metronidazole by attending physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose clinical care team indicates it would be inappropriate to include&#xD;
             him/her in the study (e.g. due to terminal illness)&#xD;
&#xD;
          -  In a patient receiving metronidazole or vancomycin, receipt of fidaxomicin within the&#xD;
             previous 3 months&#xD;
&#xD;
          -  patients unable to give informed consent for whom no consultee is available to give&#xD;
             approval&#xD;
&#xD;
          -  non-English speakers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark H Wilcox</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Teaching Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Planche</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Stanley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bradford Teaching Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW19 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Professor Mark Wilcox</investigator_full_name>
    <investigator_title>Professor of Medical Microbiology</investigator_title>
  </responsible_party>
  <keyword>clostridium difficile</keyword>
  <keyword>environment</keyword>
  <keyword>contamination</keyword>
  <keyword>fidaxomicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

